WallStSmart

Henry Schein Inc (HSIC)vsNebius Group N.V. (NBIS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 2426% more annual revenue ($13.38B vs $529.80M). NBIS leads profitability with a 15.6% profit margin vs 3.0%. NBIS appears more attractively valued with a PEG of 0.63. HSIC earns a higher WallStSmart Score of 52/100 (C-).

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 2.71

NBIS

Hold

47

out of 100

Grade: D+

Growth: 8.0Profit: 4.0Value: 5.3Quality: 5.5
Piotroski: 5/9Altman Z: 0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HSICUndervalued (+64.5%)

Margin of Safety

+64.5%

Fair Value

$229.97

Current Price

$70.82

$159.15 discount

UndervaluedFair: $229.97Overvalued
NBISUndervalued (+14.8%)

Margin of Safety

+14.8%

Fair Value

$186.91

Current Price

$177.05

$9.86 discount

UndervaluedFair: $186.91Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

NBIS2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
547.0%10/10

Revenue surging 547.0% year-over-year

PEG RatioValuation
0.638/10

Growing faster than its price suggests

Areas to Watch

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.614/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.023/10

Elevated debt levels

NBIS4 concerns · Avg: 3.5/10
Price/BookValuation
9.7x4/10

Trading at 9.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.3%3/10

ROE of 0.3% — below average capital efficiency

Debt/EquityHealth
1.063/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bull Case : NBIS

The strongest argument for NBIS centers on Revenue Growth, PEG Ratio. Profitability is solid with margins at 15.6% and operating margin at -109.8%. Revenue growth of 547.0% demonstrates continued momentum.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Bear Case : NBIS

The primary concerns for NBIS are Price/Book, EPS Growth, Return on Equity. A P/E of 4619.3x leaves little room for execution misses.

Key Dynamics to Monitor

HSIC profiles as a value stock while NBIS is a growth play — different risk/reward profiles.

NBIS carries more volatility with a beta of 1.24 — expect wider price swings.

NBIS is growing revenue faster at 547.0% — sustainability is the question.

HSIC generates stronger free cash flow (-136M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (52/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Nebius Group N.V.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Nebius Group N.V. (Ticker: NBIS) is a forward-looking technology company specializing in advanced digital solutions designed to enhance client engagement and streamline operational efficiency across diverse sectors. By harnessing the power of cloud computing, artificial intelligence, and data analytics, Nebius equips businesses to effectively manage the complexities of the digital age. With a strong portfolio of intellectual property and meaningful strategic partnerships, the company is poised to capture significant growth opportunities in the dynamic technology landscape, positioning itself as an appealing investment choice for institutional investors seeking high-growth prospects in tech-driven markets.

Visit Website →

Want to dig deeper into these stocks?